INTRODUCTION 73
Glaucoma is the leading cause of irreversible and preventable blindness worldwide. 1 It refers 74 to a heterogeneous set of progressive eye disorders characterized by optic disc cupping and 75 corresponding visual field defects.
2 Primary Open Angle Glaucoma (POAG) is the most 76 common subset and affects 3% of the Australian population above the age of 50.
3 Symptoms 77 are usually not apparent until substantial irreversible damage has occurred. Therefore we 78 need to facilitate early diagnosis in order to prevent vision loss. Approximately half of those 79 affected remain undiagnosed, 3, 4 suggesting that current screening strategies lack efficacy. 80 POAG has a strong genetic component. 5 Individuals with an affected first-degree relative are 81 9 times more likely to develop glaucoma compared with the general population. 6 The 82
Myocilin (MYOC) gene was the first gene associated with POAG.
7,8 MYOC disease-causing 83 variants have been identified in 2-4% of unselected POAG patients and in 8-36% of POAG 84 patients diagnosed before 40 years of age. [9] [10] [11] The variants are inherited in an autosomal 85 dominant fashion with high penetrance, and carriers usually demonstrate elevated intraocular 86 pressure (IOP) with an earlier age of onset than POAG patients without MYOC variants. 10 
87
There is an enrichment of MYOC variants in patients with advanced POAG, indicating a 88 progression to a more severe disease, particularly without treatment. 10 Since the discovery of 89 the MYOC gene in 1997, over 80 disease-causing variants have been described, with the 90 p.Gln368Ter variant the most common.
12 Although clear genotype-phenotype correlations 91 exist, inter-and intra-familial phenotypic variability is also well acknowledged. The 92 p.Gln368Ter variant has a variable age-related penetrance with 50% of carriers diagnosed 93 with glaucoma by 50 years of age. 13 Other disease-causing variants such as p.Pro370Leu or 94 p.Gly367Arg are more severe and are associated with complete penetrance by 50 years of 95 age. 9, 10, 14, 15 The exact mechanism of MYOC variants leading to disease has not yet been fully 96 elucidated. There is evidence to suggest that the abnormal gene protein products accumulate 97 in the trabecular meshwork contributing to outflow obstruction and ultimately increasing 98 IOP. 16, 17 99 POAG is treated by lowering IOP; it is an effective strategy to slow progression or to prevent 100 disease development, provided patients are identified early in the disease process. 18, 19 101 Lowering IOP is achieved with medical therapy, with laser or with incisional surgical 102 interventions. In the era of personalized medicine, the ability to predict disease development 103 can allow tailored, specific treatment plans for individuals. Considering the difficulties in 104 diagnosing glaucoma early, the younger age of onset for MYOC carriers compared with the 105 general population and the availability of effective preventive measures for treating POAG, 106 Participant recruitment into the ANZRAG has been described previously. 22 Patients with all 127 levels of glaucoma could be referred to the ANZRAG by clinicians. Advanced glaucoma was 128 defined as central visual field loss related to glaucoma with at least 2 of the 4 central fixation 129 squares having a pattern standard deviation probability of less than 0.5% on a reliable 130 Humphrey 24-2 field, or a mean deviation (MD) of less than -22 dB, or in the absence of 131 visual field testing, best-corrected visual acuity (BCVA) worse than 20/200 due to glaucoma. 132
Participants also needed evidence of glaucoma in the less severely affected eye characterized 133 by glaucomatous visual field defects with corresponding optic disc rim thinning. Non-134 advanced glaucoma was defined by glaucomatous visual field defects, with corresponding 135 optic disc rim thinning, including an enlarged cup-to-disc ratio (CDR) (≥0.7) or CDR 136 asymmetry (≥0.2) between both eyes. Glaucoma suspects had ocular hypertension as defined 137 by IOP >21 mmHg or had pre-perimetric glaucoma with no glaucomatous field changes. 138
Advanced and non-advanced POAG cases recruited in the ANZRAG were screened for 139 MYOC as previously described. 10 Glaucoma suspects who did not meet the advanced or non-140 advanced criteria but had a combination of ocular hypertension, young age and positive 141 family history of glaucoma were also screened. Through the proband, cascade genetic testing 142 and counselling were offered to first-degree family members over the age of 18 who were 143 either affected or unaffected. Mann-Whitney-U test was used for the assessment of differences in nonparametric data and 164
Chi square tests for categorical data. 165
166

RESULTS
167
Ninety-seven participants with a MYOC disease-causing variant were identified in the 168 ANZRAG. Of these, clinical details at presentation could be obtained for 73 (75%) 169 participants included in the study. They consisted of 43 (59%) Clinical cases and 30 (41%) 170
Genetic cases. There were 39 (53%) female and 34 (47%) male patients. The mean current 171 age was 60.9 ± 17.7 years (range 16-87 years) for Clinical cases and 44.7 ± 11.9 years (range 172 24-77 years) for Genetic cases. Genetic cases were significantly younger at presentation than 173
Clinical cases (40.6 ± 12.5 versus 47.5 ± 16.7 years, P = 0.018). At their first examination, 25 174 (83%) Genetic cases were unaffected and 5 (17%) were glaucoma suspect whereas among12 (28%) had advanced glaucoma (Figure 1 ). Among the Genetic cases, unaffected 177 individuals were significantly younger compared to glaucoma suspects (42.5 ± 10.4 versus 178 55.8 ± 13.7 years, P = 0.037). 179
The mean highest IOP (17.6 ± 3.6 versus 32.2 ± 9.7 mmHg, P < 0.001), highest CDR (0.48 ± 180 0.13 versus 0.65 ± 0.27, P = 0.006), worst MD ( Of the 52 p.Gln368Ter cases, 28 (54%) were Clinical cases and 24 (46%) were Genetic cases. 217
The mean current age was 68.4 ± 8.8 years (range 53-87 years) for Clinical cases and 44.7 ± 218 12.7 years (range 24-77 years) for Genetic cases. The mean age at presentation was 219 significantly younger among Genetic cases compared with Clinical cases (40.5 ± 13.3 versus 220 55.0 ± 9.8 years, P < 0.001). Among Genetic cases, 19 were unaffected and 5 were glaucoma 221 suspect at presentation whereas 12 Clinical cases were glaucoma suspect, 8 had non-222 advanced glaucoma and 8 had advanced glaucoma. 223
The mean highest IOP (18.0 ± 3.7 versus 29.9 ± 9.3 mmHg, P < 0.001), highest CDR (0.49 ± 224 0.14 versus 0.66 ± 0.27, P = 0.016), worst MD (-1.3 ± 1. We showed that patients identified via cascade genetic testing presented 7 years younger than 251 those identified following ophthalmic referral. The majority (83%) of carriers identified 252 through genetic testing were asymptomatic at the time of presentation whereas half of the 253 patients who had an ophthalmic referral had early signs of glaucoma and the other half 254 already had glaucoma, including 28% with advanced disease. All clinical parameters related 255 to glaucoma (IOP, CDR and MD on visual field test) were significantly worse at presentation 256 among Clinical cases compared with Genetic ones. 257
We conducted separate analyses on probands/siblings and probands/offsprings to evaluate 258 whether the age difference affected our findings. As expected, the age at presentation was 259 significantly younger in Genetic cases compared with Clinical cases within the 260 probands/children group whereas the age at presentation was similar between Clinical and 261
Genetic cases within the probands/siblings group. There were fewer siblings than offsprings 262 in the Genetic group, which can be explained by a proportion of siblings already affected by 263 glaucoma and not identified through genetic testing. In both analyses, the clinical parameters 264 associated with glaucoma were significantly less severe in Genetic cases compared with 265
Clinical cases. Forty-four percent of the siblings were identified as glaucoma suspect 266 following genetic testing results. However the siblings in the Genetic group had better 267 glaucoma parameters than the probands, despite the fact that they presented at a similar age 268 than the probands and that almost half of them had early signs of glaucoma. These findings 269 highlight the usefulness of cascade genetic testing irrespective of the age of the family 270 members. 271
Genotype-phenotype correlations have been well described for MYOC variants. [10] [11] [12] In order 272 to reduce the variability accounted for by disease-causing variants of different severity, we 273 analysed individuals carrying only the most common MYOC variant (p.Gln368Ter) 274 separately. p.Gln368Ter is usually associated with a moderate severity and displays an age-275 related penetrance with half of the carriers being diagnosed with glaucoma by 50 years of age 276 and almost all carriers diagnosed by 75 years of age.
13 When considering p.Gln368Ter 277 carriers only, individuals diagnosed early because of more severe MYOC variants are 278 excluded as shown by the older age at presentation among p.Gln368Ter carriers. Our results 279
showed that p.Gln368Ter carriers identified through genetic testing presented 15 years 280 younger than those who presented clinically. They also show better clinical parameters at 281 presentation as illustrated by lower IOPs, CDR and MD on visual field test than their 282 clinically diagnosed counterparts. Glaucoma suspects identified by ophthalmic presentation 283 were on average in their early 50s, which is in accordance with the age-related penetrance for 284 this variant. Unaffected individuals identified through genetic testing were on average in their 285 late 30s (37.1 ± 2.5 years), an age group where a minority of p.Gln368Ter carriers are 286 affected. This shows the ability of cascade genetic testing to identify gene carriers before they 287 exhibit symptoms of the disease. 288
Among the individuals carrying variants other than p.Gln368Ter, some had a more severe 289 disease with an early age of glaucoma onset. In these families, we would expect cascade 290 genetic testing to have similar positive outcomes if conducted at an early age, and we have 291 previously discussed the benefits of a genetic testing approach for minors in these families. Through our cascade testing program, we make genetic testing available to all first-degree 300 relatives but we do not contact relatives directly to promote autonomous and noncoercive 301
decisions. This approach yields a response rate of 50% which is similar to other adult-onset 302 conditions with treatment options and high penetrance genes such as inherited cancers and 303 cardiomyopathies. 24, 25 Individuals with a family history are more likely to access screening 304 for glaucoma. 26 However, in our cohort 79% (33/42) of individuals who presented clinically 305 had a family history, including 67% (16/24) who presented with glaucoma. This suggests that 306 family history may not be enough of a risk factor to diagnose at-risk individuals early. 307
Additionally, we previously showed that the majority of newly identified MYOC carriers had 308 never seen an eye specialist, 10 supporting genetic testing as an effective way to identify at-309 risk individuals in MYOC families in a more timely manner. 310
In this study, 25 individuals had no signs of glaucoma on examination following genetic 311 results. These individuals were significantly younger than those identified as glaucoma 312 suspects following genetic results. MYOC variants are highly penetrant: Age-related 313 penetrance is complete at 50 years old for MYOC variants associated with an early age of 314 onset 9, 10, 14, 15 and almost complete at 75 years old for the common p.Gln368Ter variant.
315
Therefore, these unaffected individuals are expected to develop glaucoma at some stage. 316
Interestingly, we are aware of two individual who subsequently converted to glaucoma 317 suspect in the Genetic group on follow-up. Long-term studies that follow at-risk 318 asymptomatic individuals are still needed to assess clinical outcomes, the progression of the 319 disease and the best treatment strategies for MYOC carriers. 320
Cascade genetic screening for glaucoma is a promising avenue to prevent glaucoma 321 blindness. A previous study demonstrated the acceptability of predictive genetic testing for 322 MYOC glaucoma. 20 Data from the ANZRAG have recently shown that families perceived 323 strong benefits to cascade testing as it leads to the possibility of preventive measures. 21 We 324 have previously shown that MYOC disease-causing variants are more prevalent in the 325 advanced stages of glaucoma.
10 As a result early diagnosis is important as carriers may 326 require earlier interventions and more aggressive management of their IOP. Our findings also 327 confirm that MYOC carriers respond to IOP-lowering therapy. Personalized medicine using 328 genetic information to predict disease development and to tailor preventative interventions 329 for each patient is an evolving field. This study has some potential limitations. First, there might be a recruitment bias as patients 339 who are more likely to have undiagnosed glaucoma are also the ones who will not seek 340 genetic testing and are less likely to be screened. 21 The ANZRAG recruits individuals with 341 both advanced and non-advanced POAG but has a recruitment bias toward more advanced 342 disease, which could have resulted in an overestimation of the severity in the Clinical group. 343
Second, this is a retrospective study and clinical details at the time of initial diagnosis were 344 missing for 25% of participants with a MYOC variant. Many of them had been diagnosed 345 decades ago, and as such, records of the initial presenting details no longer existed or were 346 irretrievable. However, a randomized clinical trial to study the efficacy of genetic testing for 347 glaucoma leading to better visual outcome would be impossible to conduct. So although a 348 retrospective study collecting clinical evidence has limitations, this is the first study to report 349 such findings. 
